Treatment of retinal pigment epithelial detachment with antiangiogenic therapy

Luis AriasDepartment of Ophthalmology, Bellvitge University Hospital, Barcelona, SpainPurpose: Evaluate the efficacy of pegaptanib, a selective anti-vascular endothelial growth factor (VEGF) agent, and bevacizumab, a nonselective anti-VEGF agent, for retinal pigment epithelial detachment (PED) assoc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Luis Arias
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/c598f1e30e1748de9e5ed090f0b94d17
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c598f1e30e1748de9e5ed090f0b94d17
record_format	dspace
spelling	oai:doaj.org-article:c598f1e30e1748de9e5ed090f0b94d172021-12-02T07:38:07ZTreatment of retinal pigment epithelial detachment with antiangiogenic therapy1177-54671177-5483https://doaj.org/article/c598f1e30e1748de9e5ed090f0b94d172010-04-01T00:00:00Zhttp://www.dovepress.com/treatment-of-retinal-pigment-epithelial-detachment-with-antiangiogenic-a4262https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Luis AriasDepartment of Ophthalmology, Bellvitge University Hospital, Barcelona, SpainPurpose: Evaluate the efficacy of pegaptanib, a selective anti-vascular endothelial growth factor (VEGF) agent, and bevacizumab, a nonselective anti-VEGF agent, for retinal pigment epithelial detachment (PED) associated with occult choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).Methods: Prospective, comparative, nonrandomized pilot study included patients with PED comprising &gt;50% of total lesion in subfoveal location with visual acuity (VA) 20/40&ndash;20/400 and lesions either previously untreated or treated only with photodynamic therapy/verteporfin. Seven patients received pegaptanib 0.3 mg intravitreally (IVT); eight received IVT bevacizumab 1.25 mg. Follow-up occurred every 4&ndash;6 weeks for 6 months. Reinjection of initial medication occurred if there was intra- or subretinal fluid observed by optical coherence tomography (OCT) or increased PED. Endpoints were mean changes from baseline to month 6 in VA (ETDRS) and foveal thickness.Results: At baseline, mean VA was lower, and mean foveal thickness was greater in pegaptanib versus bevacizumab-treated patients (36.1 vs 49.5 letters; 470.4 vs 321.1 &mu;m). Mean improvements to month 6 in VA and foveal thickness were greater for pegaptanib (VA: +9.1 vs +7.2 letters; foveal thickness: &minus;88.2 vs &minus;52.9 &mu;m). On average, pegaptanib-treated patients had slower but more sustained improvement in VA and foveal thickness; bevacizumab-treated patients showed rapid improvement with a slow return towards baseline. Both agents were well tolerated. Conclusion: Intravitreal injections of pegaptanib or bevacizumab are both efficacious and safe treatments for PED associated with occult CNV secondary to AMD.Keywords: bevacizumab, pegaptanib, retinal pigment epithelial detachment Luis AriasDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2010, Iss default, Pp 369-374 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Luis Arias Treatment of retinal pigment epithelial detachment with antiangiogenic therapy
description	Luis AriasDepartment of Ophthalmology, Bellvitge University Hospital, Barcelona, SpainPurpose: Evaluate the efficacy of pegaptanib, a selective anti-vascular endothelial growth factor (VEGF) agent, and bevacizumab, a nonselective anti-VEGF agent, for retinal pigment epithelial detachment (PED) associated with occult choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).Methods: Prospective, comparative, nonrandomized pilot study included patients with PED comprising &gt;50% of total lesion in subfoveal location with visual acuity (VA) 20/40&ndash;20/400 and lesions either previously untreated or treated only with photodynamic therapy/verteporfin. Seven patients received pegaptanib 0.3 mg intravitreally (IVT); eight received IVT bevacizumab 1.25 mg. Follow-up occurred every 4&ndash;6 weeks for 6 months. Reinjection of initial medication occurred if there was intra- or subretinal fluid observed by optical coherence tomography (OCT) or increased PED. Endpoints were mean changes from baseline to month 6 in VA (ETDRS) and foveal thickness.Results: At baseline, mean VA was lower, and mean foveal thickness was greater in pegaptanib versus bevacizumab-treated patients (36.1 vs 49.5 letters; 470.4 vs 321.1 &mu;m). Mean improvements to month 6 in VA and foveal thickness were greater for pegaptanib (VA: +9.1 vs +7.2 letters; foveal thickness: &minus;88.2 vs &minus;52.9 &mu;m). On average, pegaptanib-treated patients had slower but more sustained improvement in VA and foveal thickness; bevacizumab-treated patients showed rapid improvement with a slow return towards baseline. Both agents were well tolerated. Conclusion: Intravitreal injections of pegaptanib or bevacizumab are both efficacious and safe treatments for PED associated with occult CNV secondary to AMD.Keywords: bevacizumab, pegaptanib, retinal pigment epithelial detachment
format	article
author	Luis Arias
author_facet	Luis Arias
author_sort	Luis Arias
title	Treatment of retinal pigment epithelial detachment with antiangiogenic therapy
title_short	Treatment of retinal pigment epithelial detachment with antiangiogenic therapy
title_full	Treatment of retinal pigment epithelial detachment with antiangiogenic therapy
title_fullStr	Treatment of retinal pigment epithelial detachment with antiangiogenic therapy
title_full_unstemmed	Treatment of retinal pigment epithelial detachment with antiangiogenic therapy
title_sort	treatment of retinal pigment epithelial detachment with antiangiogenic therapy
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/c598f1e30e1748de9e5ed090f0b94d17
work_keys_str_mv	AT luisarias treatmentofretinalpigmentepithelialdetachmentwithantiangiogenictherapy
_version_	1718399304351088640

Treatment of retinal pigment epithelial detachment with antiangiogenic therapy

Ejemplares similares